ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 258 filers reported holding ACCELERON PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.78 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $123,105,000 | -43.2% | 715,322 | -58.6% | 0.02% | -41.7% |
| Q2 2021 | $216,590,000 | +7.0% | 1,725,955 | +15.6% | 0.04% | 0.0% |
| Q1 2021 | $202,446,000 | +30.5% | 1,492,854 | +23.1% | 0.04% | +24.1% |
| Q4 2020 | $155,093,000 | -12.4% | 1,212,243 | -23.0% | 0.03% | -21.6% |
| Q3 2020 | $177,056,000 | +21.2% | 1,573,411 | +2.6% | 0.04% | +12.1% |
| Q2 2020 | $146,136,000 | -15.7% | 1,533,911 | -20.5% | 0.03% | -28.3% |
| Q1 2020 | $173,409,000 | +34.1% | 1,929,566 | -20.9% | 0.05% | +70.4% |
| Q4 2019 | $129,298,000 | +117.6% | 2,438,669 | +62.1% | 0.03% | +107.7% |
| Q3 2019 | $59,424,000 | -2.1% | 1,504,050 | +1.7% | 0.01% | 0.0% |
| Q2 2019 | $60,729,000 | -11.2% | 1,478,314 | +0.7% | 0.01% | -13.3% |
| Q1 2019 | $68,379,000 | +2959.5% | 1,468,279 | +2501.0% | 0.02% | +1400.0% |
| Q4 2013 | $2,235,000 | – | 56,450 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |